PIVOT trial (pneumonia intravenous versus oral treatment)

M. Atkinson, T. Stephenson, M. Lakhanpaul, A. Smyth, H. Vyas, V. Weston, V. Owen, P. Lorgelly, H. Sammons, I. Choonara, L. Walton, N. Guntupalli, C. Groggins, H. Clements (Nottingham, London, Lincoln, United Kingdom)

Source: Annual Congress 2003 - Pneumonia and lower respiratory infections in children
Session: Pneumonia and lower respiratory infections in children
Session type: Thematic Poster Session
Number: 932
Disease area: Paediatric lung diseases, Respiratory infections

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Atkinson, T. Stephenson, M. Lakhanpaul, A. Smyth, H. Vyas, V. Weston, V. Owen, P. Lorgelly, H. Sammons, I. Choonara, L. Walton, N. Guntupalli, C. Groggins, H. Clements (Nottingham, London, Lincoln, United Kingdom). PIVOT trial (pneumonia intravenous versus oral treatment). Eur Respir J 2003; 22: Suppl. 45, 932

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
A clinical and outcomes assessment of the management of community-acquired pneumonia (CAP): a multinational, prospective, double-blind comparison of moxifloxacin to standard first-line oral monotherapy or combination regimen
Source: Eur Respir J 2001; 18: Suppl. 33, 189s
Year: 2001

High-dose versus low-dose prednisolone in symptomatic patients with post-COVID-19 diffuse parenchymal lung abnormalities: an open-label, randomised trial (the COLDSTER trial)
Source: Eur Respir J, 59 (2) 2102930; 10.1183/13993003.02930-2021
Year: 2022



Efficacy, safety and tolerability of 3 day azithromycin (A) versus 10-day conventional treatment (CT) in the treatment of children with acute asthma exacerbation (AE)
Source: Eur Respir J 2005; 26: Suppl. 49, 135s
Year: 2005

Randomised controlled trial of sequential intravenous and oral azithromycin compared with intravenous ceftriaxone followed by cefixime both in combination with clarithromycin in hospitalized patients with community-acquired pneumonia
Source: Annual Congress 2011 - Antimicrobial treatment and resistance in lower respiratory tract infections
Year: 2011

Adjunctive treatment with oral dexamethasone in non-ICU patients hospitalised with community-acquired pneumonia: a randomised clinical trial
Source: Eur Respir J, 58 (2) 2002535; 10.1183/13993003.02535-2020
Year: 2021



Safety and benefit of adjunctive systemic corticosteroid therapy in the management of severe, smear positive pulmonary tuberculosis (SSP-PTB); an interim analysis of a randomized controlled trial
Source: Annual Congress 2012 - Tuberculosis: clinical findings II
Year: 2012


Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial
Source: Eur Respir J, 56 (6) 2002808; 10.1183/13993003.02808-2020
Year: 2020



“Stepping down” in mild-to-moderate asthmatic children being well controlled while receiving low doses of inhaled corticosteroids (ICS): Daily vs. cyclical ICS administration (prospective, randomized, multicentre, open-label trial)
Source: Annual Congress 2013 –Asthma treatment and management in children
Year: 2013


A phase II, randomised, placebo controlled trial of 12 weeks treatment with an oral p38 inhibitor in patients with COPD on a background of ICS/LABA
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013

Open-label, randomized, comparative trial of the efficacy of levofloxacin versus clarithromycin SR therapy in complicated infectious exacerbation of COPD
Source: Eur Respir J 2007; 30: Suppl. 51, 674s
Year: 2007

A new user cohort study comparing the risk of pneumonia in inhaled corticosteroid (ICS) vs. long-acting bronchodilator (LABD) regimens in COPD
Source: Annual Congress 2013 –Risk factors for COPD and lung function decline
Year: 2013

Efficacy, safety and tolerability of 3 day azithromycin versus 10-day amoxillin/clavulanic acid in the treatment of children with pneumonia
Source: Eur Respir J 2003; 22: Suppl. 45, 143s
Year: 2003

Efficacy and safety of VR475 (budesonide suspension delivered by the VR475 Inhalation System) as add-on treatment in patients with severe asthma (CLEARCUT Study)
Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies
Year: 2019


No differences in early or late community-acquired pneumonia outcomes in patients treated with IV ceftriaxone plus oral clarithromycin extended-release tablets versus IV levofloxacin plus oral placebo
Source: Eur Respir J 2003; 22: Suppl. 45, 335s
Year: 2003

Randomized clinical trial (RCT) comparing formoterol vs. salbutamol plus ipratropium bromide in the treatment of acute asthma exacerbation (AE) at emergency room (ER)
Source: Eur Respir J 2005; 26: Suppl. 49, 503s
Year: 2005

Effectiveness of azithromycin (AZ) in patients with community-acquired pneumonia (CAP): an evidenced-based meta-analysis of randomized controlled trials (RCTs)
Source: Eur Respir J 2001; 18: Suppl. 33, 137s
Year: 2001

Pivot trial A multicentre randomised controlled equivalence trial comparing oral amoxycillin and intravenous penicillin for community acquired pneumonia in children
Source: Eur Respir J 2004; 24: Suppl. 48, 714s
Year: 2004

Late Breaking Abstract - Adjunctive treatment with oral dexamethasone in adults hospitalised with community-acquired pneumonia: a randomised clinical trial
Source: Virtual Congress 2020 – ALERT: Infection in adults and children
Year: 2020




A comparison of intravenous versus oral administration of corticosteroids in the treatment of patients admitted to the hospital with an exacerbation of COPD
Source: Eur Respir J 2004; 24: Suppl. 48, 64s
Year: 2004

LATE-BREAKING ABSTRACT: A dose-ranging study of dupilumab in patients (pts) with uncontrolled asthma despite use of inhaled corticosteroids plus a long-acting beta-agonist (ICS/LABA): Final data
Source: International Congress 2015 – Hot topics on airway diseases: new horizons in treatment
Year: 2015